Table 1.

Incidence of the most common adverse events following immunisation (incidence ≥ 10%) with COVID-19 vaccines in randomised, controlled trials [14, 15]

	BNT162b2 primary course		mRNA-1273 primary course
	Age 12–15 yrsa	Age 16–55 yrs	Age 18–64 yrs	Age ≥ 65 yrs
Cutaneous reactions (incidence %)
IS pain	91	89	93	88
IS swelling	9	11	15	13
IS redness	9	< 10	11	< 10
Systemic reactions (incidence %)
Fatigue	78	70	72	65
Headache	76	65	69	53
Muscle pain	42	46	65	52
Chills	49	42	50	33
Joint pain	20	28	49	40
Fever	24	18	17	< 10
Nausea/vomiting	< 8	< 10	26	15
Lymphadenopathy/axillary swelling	< 8	< 10	22	13

BNT162b2 Pfizer BioNTech BNT162b2 COVID-19 vaccine, IS injection site, mRNA-1273 Moderna mRNA-1273 COVID-19 vaccine

^aThe most common adverse events following immunisation were defined as incidence ≥ 8% in this population